Background: The presently available pharmaceutical aids in smoking cessation possess a rather limited effectiveness. Therefore, we have synthesized a series of immunoconjugates that stimulate the induction of antibodies which may bind nicotine in the blood, thereby preventing it from passing the blood-brain barrier. Thus, the reinforcing action of nicotine in the brain, which is the driving force in tobacco smoking, should be abolished. Objective: The present study was undertaken to test this notion in a long-term relapse model in rats, measuring the reinstatement of nicotine-seeking behavior, following active immunization with IP18-KLH, one of our immunoconjugates. Methods: Male Wistar rats were immunized with a nicotine-KLH conjugate (nicotine immunogen) and Freund’s adjuvant after having been trained to meet the criteria of stable nicotine self-administration on a fixed ratio (FR3) schedule. The rats were subsequently extinguished from nicotine self-administration behavior and finally, as extinction was completed, they were exposed to small, priming doses of nicotine, which previously have been shown to reinstate the nicotine-seeking behavior. The antibody titers were measured by ELISA. Results: It was found that rats with high titers (>1:10,000) of antibodies against nicotine, in contrast to those with low/no nicotine selective antibodies, do not reinstate nicotine self-administration behavior when they are exposed to nicotine. Conclusions: Our findings indicate that active immunization against nicotine may effectively abolish the reinforcing action of nicotine in brain, an effect which is critical for relapse in nicotine dependence. These data suggest the potential utility of active immunization in smoking cessation programs.

Keywords:
Nicotine, Vaccine, Self-administration, Immunoconjugate
1.
US Department of Health and Human Services: The Health Consequences of Smoking: Nicotine Addiction: Anonymous. A Report of the Surgeon General. DHHS Publ. 1988;88-8406.
2.
Doll R, Peto R, Wheatley K, Gray R, Sutherland I: Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ 1994;309:901–911.
3.
WHO Website: Anonymous. www.who.int/archives/toalert/4-96/index.html, 1996.
4.
Grenhoff J, Aston-Jones G, Svensson TH: Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 1986;128:351–358.
5.
Imperato A, Mulas A, Di Chiara G: Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1986;132:337–338.
6.
Henningfield JE, Miyasato K, Jasinski DR: Cigarette smokers self-administer intravenous nicotine. Pharmacol Biochem Behav 1983;19:887–890.
7.
Goldberg SR, Spealman RD, Goldberg DM: Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 1981;214:573–575.
8.
Risner ME, Goldberg SR: A comparison of nicotine and cocaine self-administration in the dog: Fixed-ratio and progressive-ratio schedules of intravenous drug infusion. J Pharmacol Exp Ther 1983;224:319–326.
9.
Corrigall WA, Coen KM: Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 1989;99:473–478.
10.
Corrigall WA, Franklin KB, Coen KM, Clarke PB: The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 1992;107:285–289.
11.
DSM-IV-TR: Substance-Related Disorders: Anonymous. Diagnostic and Statistical Manual of Mental Disorders. Washington, American Psychiatric Association, 2000, pp 191–295.
12.
Hunt WA, Barnett LW, Branch LG: Relapse rates in addiction programs. J Clin Psychol 1971;27:455–456.
13.
Cohen S, Lichtenstein E, Prochaska JO, Rossi JS, Gritz ER, Carr CR, Orleans CT, Schoenbach VJ, Biener L, Abrams D, et al: Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. Am Psychol 1989;44:1355–1365.
14.
Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2000;4:CD000031.
15.
Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685–691.
16.
Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR: Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974;252:708–710.
17.
Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greenstein JL, Gefter ML, Exley MA, Swain PA, Briner TJ: Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996;2:1129–1132.
18.
Svensson TH, Johansson AM: Hapten-carrier protein conjugates for treatment of nicotine dependence. Patent WO 99/61054, 1999.
19.
de Villiers SHL, Lindblom N, Kalayanov G, Gordon S, Malmerfelt A, Johannson AM, Svensson TH: Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002;69:247–253.
20.
Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, Naso R, Fattom A: A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000;65:191–198.
21.
Spealman RD, Barrett-Larimore RL, Rowlett JK, Platt DM, Khroyan TV: Pharmacological and environmental determinants of relapse to cocaine-seeking behavior. Pharmacol Biochem Behav 1999;64:327–336.
22.
Stewart J: Pathways to relapse: The neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiatry Neurosci 2000;25:125–136.
23.
Chiamulera C, Borgo C, Falchetto S, Valerio E, Tessari M: Nicotine reinstatement of nicotine self-administration after long-term extinction. Psychopharmacology (Berl) 1996;127:102–107.
24.
Stewart J, de Wit H: Reinstatement of drug-taking behavior as a method of assessing incentive motivational properties of drugs; in Bozarth MA (ed): Methods of Assessing the Reinforcing Properties of Abused Drugs. New York, Springer, 1987, pp 211–227.
25.
Shaham Y, Adamson LK, Grocki S, Corrigall WA: Reinstatement and spontaneous recovery of nicotine seeking in rats. Psychopharmacology (Berl) 1997;130:396–403.
26.
Chiamulera C, Quartaroli M, Tessari M: Pharmacological Investigations of Short and Long Term Relapse of Responding for Nicotine in Rats. 3rd SRNT Europe Conference, Paris, 2001, pp 19–22.
27.
Schilstrom B, De Villiers S, Malmerfelt A, Svensson TH, Nomikos GG: Nicotine-induced Fos expression in the nucleus accumbens and the medial prefrontal cortex of the rat: Role of nicotinic and NMDA receptors in the ventral tegmental area. Synapse 2000;36:314–321.
28.
Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD: Cocaine vaccines: Antibody protection against relapse in a rat model. Proc Natl Acad Sci USA 2000;97:6202–6206.
29.
Benowitz NL, Jacob P III: Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 1984;35:499–504.
30.
Malin DH, Lake JR, Lin A, Saldana M, Balch L, Irvin ML, Chandrasekara H, Alvarado CL, Hieda Y, Keyler DE, Pentel PR, Ennifar S, Basham LE, Naso R, Fattom A: Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 2001;68:87–92.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.